Reduced expression of decay-accelerating factor 1 on CD4+ T cells in murine systemic autoimmune disease

Arthritis and Rheumatism

Volumn 56, Issue 6, 2007, Pages 1934-1944

  Cauvi, David M ^a   Cauvi, Gabrielle ^a   Pollard, K Michael ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECAY ACCELERATING FACTOR; DECAY ACCELERATING FACTOR 1; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; MERCURY; UNCLASSIFIED DRUG; DECAY ACCELERATING FACTOR 1, MOUSE; DECAY-ACCELERATING FACTOR 1, MOUSE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; C57BL 10 MOUSE; CD4+ T LYMPHOCYTE; CELL SELECTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DBA 2 MOUSE; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; MEMORY T LYMPHOCYTE; MOUSE; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; STATISTICAL ANALYSIS; ANIMAL; AUTOIMMUNITY; B LYMPHOCYTE; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; DBA MOUSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; ANTIGENS, CD44; ANTIGENS, CD55; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION; INTERLEUKIN-4; MERCURY; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; MICE, INBRED NZB; MICE, KNOCKOUT; RNA, MESSENGER;

EID: 34447559857     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22639     Document Type: Article

References (47)

1. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu Rev Immunol 1989;7: 35-58.
2. Song WC. Membrane complement regulatory proteins in autoimmune and inflammatory tissue injury. Curr Dir Autoimmun 2004;7:181-99.
3. Spicer AP, Seldin MF, Gendler SJ. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes: duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J Immunol 1995;155:3079-91.
4. Lin F, Fukuoka Y, Spicer A, Ohta R, Okada N, Harris CL, et al. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes: exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001;104: 215-25.
5. Miwa T, Sun X, Ohta R, Okada N, Harris CL, Morgan BP, et al. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specific-ity. Immunology 2001;104:207-14.
6. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995;59:1177-82.
7. Van Denderen BJ, Pearse MJ, Katerelos M, Nottle MB, Du ZT, Aminian A, et al. Expression of functional decay-accelerating factor (CD55) in transgenic mice protects against human complement-mediated attack. Transplantation 1996;61:582-8.
8. Liu J, Miwa T, Hilliard B, Chen Y, Lambris JD, Wells AD, et al. The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 2005;201:567-77.
9. Heeger PS, Lalli PN, Lin F, Valujskikh A, Liu J, Muqim N, et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005;201:1523-30.
10. Longhi MP, Harris CL, Morgan BP, Gallimore A. Holding T cells in check - a new role for complement regulators? Trends Immunol 2006;27:102-8.
11. Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, et al. Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol 2002;161:1077-86.
12. Pollard KM, Lee DK, Casiano CA, Bluthner M, Johnston MM, Tan EM. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J Immunol 1997;158:3521-8.
13. Hultman P, Nielsen JB. The effect of toxicokinetics on murine mercury-induced autoimmunity. Environ Res 1998;77:141-8.
14. Warfvinge K, Hansson H, Hultman P. Systemic autoimmunity due to mercury vapor exposure in genetically susceptible mice: dose-response studies. Toxicol Appl Pharmacol 1995;132:299-309.
15. Hultman P, Lindh U, Horsted-Bindslev P. Activation of the immune system and systemic immune-complex deposits in Brown Norway rats with dental amalgam restorations. J Dent Res 1998; 77:1415-25.
16. Hultman P, Johansson U, Turley SJ, Lindh U, Enestrom S, Pollard KM. Adverse immunological effects and autoimmunity induced by dental amalgam and alloy in mice. FASEB J 1994;8:1183-90.
17. Pollard KM, Hultman P. Effects of mercury on the immune system. Met Ions Biol Syst 1997;34:421-40.
18. Ochel M, Vohr HW, Pfeiffer C, Gleichmann E. IL-4 is required for the IgE and IgG1 increase and IgG1 autoantibody formation in mice treated with mercuric chloride. J Immunol 1991;146:3006-11.
19. Kono DH, Balomenos D, Pearson DL, Park MS, Hildebrandt B, Hultman P, et al. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-γ and not Th1/Th2 imbalance. J Immunol 1998;161:234-40.
20. Bagenstose LM, Salgame P, Monestier M. Mercury-induced autoimmunity in the absence of IL-4. Clin Exp Immunol 1998;114: 9-12.
21. Hultman P, Johansson U, Dagnaes-Hansen F. Murine mercury-induced autoimmunity: the role of T-helper cells. J Autoimmun 1995;8:809-23.
22. Johansson U, Sander B, Hultman P. Effects of the murine genotype on T cell activation and cytokine production in murine mercury-induced autoimmunity. J Autoimmun 1997;10:347-55.
23. Pollard KM, Pearson DL, Hultman P, Deane TN, Lindh U, Kono DH. Xenobiotic acceleration of idiopathic systemic autoimmunity in lupus-prone BXSB mice. Environ Health Perspect 2001;109: 27-33.
24. Pollard KM, Arnush M, Hultman P, Kono DH. Costimulation requirements of induced murine systemic autoimmune disease. J Immunol 2004;173:5880-7.
25. Van Vliet E, Uhrberg M, Stein C, Gleichmann E. MHC control of IL-4-dependent enhancement of B cell la expression and Ig class switching in mice treated with mercuric chloride. Int Arch Allergy Immunol 1993;101:392-401.
26. Cauvi DM, Cauvi G, Pollard KM. Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Spl. J Immunol 2006;177:3837-47.
27. Giulietti A, Overbergh L, Valckx D, Decallonne B, Bouillon R, Mathieu C. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001;25: 386-401.
28. Ohta R, Imai M, Fukuoka Y, Miwa T, Okada N, Okada H. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes. Microbiol Immunol 1999;43:1045-56.
29. Kono DH, Park MS, Szydlik A, Haraldsson KM, Kuan JD, Pearson DL, et al. Resistance to xenobiotic-induced autoimmunity maps to chromosome 1. J Immunol 2001;167:2396-403.
30. Biancone L, Andres G, Ahn H, Lim A, Dai C, Noelle R, et al. Distinct regulatory roles of lymphocyte costimulatory pathways on T helper type-2 mediated autoimmune disease. J Exp Med 1996; 183:1473-81.
31. Haggqvist B, Hultman P. Murine metal-induced systemic autoimmunity: baseline and stimulated cytokine mRNA expression in genetically susceptible and resistant strains. Clin Exp Immunol 2001;126:157-64.
32. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197:777-88.
33. Sogabe H, Nangaku M, Ishibashi Y, Wada T, Fujita T, Sun X, et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 2001;167:2791-7.
34. Lin F, Salant DJ, Meyerson H, Emancipator S, Morgan BP, Medof ME. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol 2004;172:2636-42.
35. Lin F, Kaminski HJ, Conti-Fine BM, Wang W, Richmonds C, Medof ME. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 2002;110:1269-74.
36. Lawson BR, Baccala R, Song J, Croft M, Kono DH, Theofilopoulos AN. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J Exp Med 2004;199:547-57.
37. Longhi MP, Sivasankar B, Omidvar N, Morgan BP, Gallimore A. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement- independent manner. J Immunol 2005; 175:7098-102.
38. Banda NK, Kraus DM, Muggli M, Bendele A, Holers VM, Arend WP. Prevention of collagen-induced arthritis in mice transgenic for the complement inhibitor complement receptor 1-related gene/protein y. J Immunol 2003;171:2109-15.
39. Bao L, Haas M, Boackle SA, Kraus DM, Cunningham PN, Park P, et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002;168:3601-7.
40. Oldstone MB, Lewicki H, Thomas D, Tishon A, Dales S, Patterson J, et al. Measles virus infection in a transgenic model: virus-induced immunosuppression and central nervous system disease. Cell 1999;98:629-40.
41. Slifka MK, Homann D, Tishon A, Pagarigan R, Oldstone MB. Measles virus infection results in suppression of both innate and adaptive immune responses to secondary bacterial infection. J Clin Invest 2003;111:805-10.
42. Sekine H, Reilly CM, Molano ID, Gamier G, Circolo A, Ruiz P, et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001;166:6444-51.
43. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is protective for lupus disease independent of C3. J Immunol 2002; 168:1036-41.
44. Song WC. Complement regulatory proteins and autoimmunity. Autoimmunity 2006;39:403-10.
45. Capasso M, Durrant LG, Stacey M, Gordon S, Ramage J, Spendlove I. Costimulation via CD55 on human CD4+ T cells mediated by CD97. J Immunol 2006;177:1070-7.
46. Legembre P, Daburon S, Moreau P, Moreau JF, Taupin JL. Modulation of Fas-mediated apoptosis by lipid rafts in T lymphocytes. J Immunol 2006;176:716-20.
47. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999;283:680-2.